Investigator-Initiated Study Program for Diabetes
The Investigator-Initiated Study (IIS) Program for Diabetes aims at advancing the delivery of quality healthcare by supporting investigator original research that will enhance the understanding of disease entities and their treatment. This program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research.
- Boehringer Ingelheim works to discover and develop innovative, safe and effective ways to treat and prevent some of the world's most challenging diseases. The Boehringer Ingelheim program for investigator-initiated studies in diabetes was established to provide study drug and/or possible financial support for independent clinical research sponsored by the investigator.
- The goal of this study program is to expedite the evaluation and approval of requests for unsolicited research support from physicians and other qualified researchers. Independent investigator original research will be supported to enhance the understanding of diabetes.
- In accordance with ICH E6-Good Clinical Practice the sponsor-investigator is responsible for planning, design, execution, analyses, and disclosure of study relevant information for the IIS. This is to ensure an independent research approach.
Key Areas of Interest for Linagliptin IIS-Proposals
1. Prediabetes and Pathophysiology New therapeutic options of linagliptin in prediabetes and type 2 diabetes
|
2. Patients and Care
|
|
3. Incretin Effects
Effects of incretin mimetics on mechanism and actions of relevant biological pathways
|
4. DPP-4 Inhibition
New insights in the pathophysiology and biochemical pathways of DPP-4 inhibition focusing on an ubiquitary enzyme and transfer into clinical reality
|
|
5. Renal, Cardiovascular and further Complications of Diabetes
|
6. Alpha- and Beta-Cell Function Effects of linagliptin on alpha- and beta-cells in terms of function, survival rate and regeneration with focus on new biomarker concepts and/or (im)balance of insulin and glucagon secretion |
Not to restrict scientific creativity other research focus areas will be considered as well.
Grant Application - either brief summaries or full proposals are accepted
Please fill out the relevant form and send it to Boehringer Ingelheim:
Info.IIS-Diabetes@boehringer-ingelheim.com
After we received your online-application a local representative of
Boehringer Ingelheim will contact you.
